Choo C R, Danjoux C, Morton G C
Department of Radiation Oncology, Toronto-Sunnybrook Regional Cancer Center, University of Toronto, Toronto, Ontario, Canada.
Can J Urol. 2000 Jun;7(3):1043-50.
Patients with pathological stage T3 and/or margin positive prostate cancer after radical prostatectomy have a high risk of tumor recurrence, usually heralded by rising PSA. Adjuvant therapy such as radiotherapy and/or hormone therapy needs to be explored to provide a better outcome. To date the exact role and result of adjuvant therapy remains unclear. However there has been increasing suggestion that adjuvant radiotherapy improves local control and disease free survival. Also adjuvant hormone therapy may play a role in this group of patients with a high metastatic potential. This review article addresses the clinical significance of PT3 and/or margin positive prostate cancer and explores the rationale behind considering adjuvant therapy including postoperative radiotherapy and/or hormone therapy.
根治性前列腺切除术后病理分期为T3和/或切缘阳性的前列腺癌患者肿瘤复发风险高，通常以前列腺特异性抗原（PSA）升高为先兆。需要探索如放疗和/或激素治疗等辅助治疗方法以获得更好的治疗效果。迄今为止，辅助治疗的确切作用和效果仍不明确。然而，越来越多的证据表明辅助放疗可改善局部控制率和无病生存率。此外，辅助激素治疗可能在这组具有高转移潜能的患者中发挥作用。这篇综述文章阐述了PT3和/或切缘阳性前列腺癌的临床意义，并探讨了考虑辅助治疗（包括术后放疗和/或激素治疗）的理论依据。
